Severe combined immunodeficiency with sensitivity to ionizing radiation: Clinical Trials

1 completed, 1 recruiting, 1 terminated. 3 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	3	Completed 1, Recruiting 1, Terminated 1
Phase 1	1	Recruiting 1

Follow Severe combined immunodeficiency with sensitivity to ionizing radiation: new trials by email Literature Review of Severe combined immunodeficiency with sensitivity to ionizing radiation trials Research Report on Severe combined immunodeficiency with sensitivity to ionizing radiation

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) ARTEGENE drug product - Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency	Phase 1 / Phase 2	Recruiting	Assistance Publique - Hôpitaux de Paris	7	2023-07-19	2026-03-27
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) Tulisokibart, Companion Diagnostic (CDx) Testing, Placebo - Ulcerative Colitis	Phase 2	Completed	Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	178	2021-07-14	2026-09-01
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM) Placebo, Amatuximab, Pemetrexed - Mesothelioma, Malignant	Phase 2	Terminated	Morphotek	124	2015-11-03	2020-03-17

Narrower conditions

Colitis, Ulcerative (1)  ·  Mesothelioma, Malignant (1)  ·  Severe Combined Immunodeficiency (1)  ·  Xeroderma Pigmentosum, Complementation Group F (1)

Broader conditions

Adenoma (1)  ·  Colitis (1)  ·  Colonic Diseases (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  DNA Repair-Deficiency Disorders (1)  ·  Digestive System Diseases (1)  ·  Gastroenteritis (1)  ·  Gastrointestinal Diseases (1)  ·  Genetic Diseases, Inborn (1)  ·  Immune System Diseases (1)  ·  Immunologic Deficiency Syndromes (1)  ·  Infant, Newborn, Diseases (1)  ·  Inflammatory Bowel Diseases (1)  ·  Intestinal Diseases (1)  ·  Lung Diseases (1)

Interventions

Cisplatin (1)  ·  Pemetrexed (1)  ·  amatuximab (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (1)  ·  Morphotek (1)  ·  Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)

Countries

France (3)  ·  Australia (2)  ·  Italy (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Belgium (1)  ·  Canada (1)  ·  Czechia (1)  ·  Georgia (1)  ·  Germany (1)  ·  Hungary (1)  ·  Israel (1)  ·  Poland (1)

Top investigators

Chantal Lagresle-Peyrou, MD (1)

Results publications

PMID 39321363

NIH funding

2014 (1), 2019 (1), 2023 (1)